DMRA Damora Therapeutics, Inc.

CIK 0001800315 18 ready 8-Ks latest May 4, 2026, 7:59 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline Risk accumulating: auditor change (2), repeated leadership change (2), risk events (2)

Ready 8-Ks 18

Latest filing May 4, 2026, 7:59 PM ET

Top materiality 0.90

Event mix other_material ×7 · leadership ×5 · regulatory ×3

Sentiment 4 pos · 2 neg · 12 neu

Executive change recent →

Recent 8-K filings for DMRA

Highest-materiality recent filing

Galecto CEO departs; authorized shares increased to 500M; outstanding shares jump to 43.6M after preferred conversion

February 10, 2026, 6:59 PM ET leadership materiality 0.90 negative item 5.02 item 5.03 item 5.07 item 8.01 item 9.01 ◈ Governance Changes

CEO Hans T. Schambye departs effective Feb 10, 2026; COO Sherwin Sattarzadeh appointed interim principal executive officer.
Shareholders approve increase in authorized common shares from 300M to 500M, plus Cayman Islands redomestication.

Read filing →

May 4, 2026, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change ×2

Damora Therapeutics CFO Lori Firmani to depart May 1; Brian Burkavage appointed principal financial officer

Effective May 1, 2026, Lori Firmani will cease serving as CFO of Damora Therapeutics.
March 23, 2026, 7:59 PM ET leadership materiality 0.80 positive item 5.02 item 7.01 item 9.01

Damora Therapeutics appoints Jennifer Jarrett as CEO, adds two directors, names chairman

Jennifer Jarrett appointed President and CEO, effective March 30, 2026; also joins board.
March 10, 2026, 7:59 PM ET other material materiality 0.70 positive item 2.02 item 5.03 item 7.01 item 9.01 ◈ Governance Changes

Galecto rebrands as Damora Therapeutics (DMRA); $535M cash; DMR-001 IND mid-2026

Name changed from Galecto to Damora Therapeutics; trades on Nasdaq as DMRA from March 10, 2026.
February 11, 2026, 6:59 PM ET other material materiality 0.85 neutral item 1.01 item 9.01 ◈ Material Agreements

Galecto raises $295.9M in equity offering; funds Phase 3 of DMR-001

Offering of 14,473,685 shares at $19.00 each; underwriters' option for 2,171,052 additional shares exercised in full.
February 10, 2026, 6:59 PM ET leadership materiality 0.90 negative item 5.02 item 5.03 item 5.07 item 8.01 item 9.01 ◈ Governance Changes

Galecto CEO departs; authorized shares increased to 500M; outstanding shares jump to 43.6M after preferred conversion

CEO Hans T. Schambye departs effective Feb 10, 2026; COO Sherwin Sattarzadeh appointed interim principal executive officer.
January 6, 2026, 6:59 PM ET leadership materiality 0.60 neutral item 3.02 item 5.02 item 9.01

Galecto appoints Sherwin Sattarzadeh as COO; issues warrant to Paramora

Sherwin Sattarzadeh appointed COO effective Jan 5, 2026; base salary $540,000, target bonus 40%.
November 10, 2025, 6:59 PM ET M&A materiality 0.90 neutral item 1.01 item 5.03 item 2.01 item 3.02 item 5.02 item 7.01 item 9.01 ◈ Governance Changes◈ M&A Transactions

Galecto acquires Damora, raises ~$285M PIPE, appoints Fairmount-affiliated directors

Galecto acquired Damora Therapeutics; issued 265,309 common shares, 16,366 Series B and 4,241 Series C preferred shares to Damora stockholders.
October 7, 2024, 7:59 PM ET M&A materiality 0.60 neutral item 1.01 item 2.01 item 3.02 item 5.02 item 5.03 item 7.01 item 9.01

Galecto acquires global rights to BRM-1420 dual ENL-YEATS/FLT3 inhibitor for AML

Galecto issued 62,594 common shares and 160.562 Series A convertible preferred shares (convertible into 160,562 common) to Bridge Medicines.
March 26, 2024, 7:59 PM ET regulatory materiality 0.65 negative item 8.01

Galecto transfers to Nasdaq Capital Market; granted 180-day extension for bid price compliance

Transferred listing from Nasdaq Global Select to Nasdaq Capital Market effective March 22, 2024.

Executive changes

Appointed

Brian Burkavage

principal financial officer and principal accounting officer

DMRA · Damora Therapeutics, Inc.

Effective: 2026-05-01
Filed: May 4, 2026, 7:59 PM ET

the Board appointed Brian Burkavage, the Company’s current Senior Vice President, Finance, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Time.

Departed

Lori Firmani

Chief Financial Officer

DMRA · Damora Therapeutics, Inc.

Effective: 2026-05-01
Successor: Brian Burkavage
Filed: May 4, 2026, 7:59 PM ET

the Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) determined that, effective as of May 1, 2026 (the “Effective Time”), Lori Firmani would cease serving as the Company’s Chief Financial Officer.

Appointed

Amy Wechsler

Director

DMRA · Damora Therapeutics, Inc.

Effective: 2024-10-11
Filed: October 15, 2024, 7:59 PM ET

appointed Amy Wechsler to join the Board, effective as of October 11, 2024.

Materiality & sentiment trend

Max materiality 0.90 · Median 0.57 · Most common event other_material

4 positive 2 negative 12 neutral

source · DMRA on sec.gov